Document:

Exhibit 4.1

                                 LOAN AGREEMENT

                              entered into between

1.       Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen, Germany
                                - hereinafter also referred to as the "COMPANY"-

2. DNAPrint genomics, Inc., 900 Cocoanut Ave. Sarasotar, FL 34236, USA
                                     - hereinafter also referred to as "LENDER"-

         Hereinafter this loan agreement is also referred to as the AGREEMENT.

1.       GRANT OF LOAN

1.1      The Lender herewith grants a loan in the total amount of EUR 140,000.00
         (GRANTED  LOAN)  to  the  Company  payable  in one  installment  of EUR
         140,000.00.

1.2      The  Granted  Loan  shall  be  paid  out on  December  27,  2004 to the
         Company's  bank account 704 545301 with Deutsche  Bank AG,  Leverkusen,
         bank code 375 700 64. The credit entry in the  Company's  account shall
         be  decisive.  The  payment  shall be made by bank  wire  transfer,  in
         immediately available funds, free of all costs and charges.

2.       REPAYMENT

         Subject to clause 3 and unless this Agreement is terminated earlier the
         Granted Loan is due for  repayment on December 31, 2005 (the DUE DATE).
         If this  Agreement  is  terminated  pursuant to Clause 5(a) to 4(d) the
         Granted Loan is due and repayable two weeks after the  termination  has
         become  effective.  If this Agreement is terminated  pursuant to Clause
         5(e) the Granted Loan is due immediately.

3.       CONVERSION

3.1      Instead of repaying the Granted Loan and interest  pursuant to Clause 4
         in cash the  Company  is  entitled  to repay the  Granted  Loan and the
         interest  by  issuing  non-par  value   registered   shares  as  voting
         preference  shares class B with a proportional  amount of the Company's
         share capital of EUR 1.00 each (PREFERRED B) to the Lender.  The Lender
         is entitled to convert its repayment and interest claims into Preferred
         B as provided for in this Clause 3 (the Company's and DNAPrint's rights
         described in this Clause are also referred to as the CONVERSION RIGHT).

3.2      The Company is entitled to exercise  the  Conversion  Right at any time
         prior  to the Due  Date,  provided  it did  not  rescind  the  DNAPrint
         Investment  Agreement  of  September  2004.  DNAPrint  is  entitled  to
         exercise the Conversion Right if the authorized capital provided for in
         sec.  11.1 of the DNAPrint  Investment  Agreement of September  2004 is

                                       1
<PAGE>

         registered with the commercial  register or the Company's  shareholders
         agreed to provide the new Preferred B in any other way.

3.3      Each  Preferred B shall grant the right to  participate in profits from
         1st January, 2005. Each Preferred B shall grant one vote.

3.4      The Company is entitled  to  exercise  or fulfil the  Conversion  Right
         either  by  issuing  the  Preferred  B in  consideration  of cash or in
         consideration  of a contribution in kind each as described in Subclause
         3.5.

3.5      The  Company  may  request  at its sole  discretion  -  subject  to the
         subscription  rights of the  Company's  shareholders  - from the Lender
         either

         (a)      To  subscribe  for  Preferred  B issued  in  consideration  of
                  contributing the Lender's  repayment and interest claims under
                  this  Agreement in relation to the Granted Loan to the Company
                  (by assigning or waiving it); or

         (b)      To subscribe  for Preferred B issued at the lowest issue price
                  pursuant to s. 9 of the German Stock  Corporations  Act (AKTG)
                  in consideration of a cash  contribution and to contribute the
                  Lender's repayment and interest claims under this Agreement in
                  relation  to the  Granted  Loan to the  Company as  additional
                  payments in the sense of s. 272 sub-sec. 2 no. 4 of the German
                  Commercial Code (HGB).

3.6      The  Company  shall  inform  the  Lender  about  the  exercise  of  the
         Conversation  Right  without undue delay but not later than one week in
         advance.  If the  Conversion  Right is  exercised  by the  Lender,  the
         Company shall  undertake all steps  necessary to effect the  conversion
         without undue delay. The Lender undertakes to make all declarations and
         acts which are  necessary  or  appropriate  to effect the  Conversation
         Right  without  undue  delay at the  request of the  Company  after the
         Company  has  provided  the  Lender  with  all  documents  required  in
         connection  with the  issuance of new  Preferred  B as provided  for in
         Subclause 3.5.

3.7      The  number of  Preferred  B to be issued by the  Company to the Lender
         pursuant to this Clause shall be  calculated  on an assumed issue price
         of EUR 9.27. For  calculating the number of Preferred B to be issued in
         relation to  Subclause  3.5(a)  that means the sum of the Granted  Loan
         plus  interest  has to be divided by 9.27 and in relation to  Subclause
         3.5(b)  that means the sum of the  Granted  Loan plus  interest  has to
         divided by 8.27.

4.       INTEREST

4.1      The Granted Loan shall bear interest. The interest rate shall be twelve
         (12) per cent per annum.

4.2      The interest is to be  calculated  pro rata  temporis on the basis of a
         year with 360 days with 12 months of 30 days each, compounded annually.
         In the case of repayment of the Granted Loan  pursuant to Clause 2, the
         payment  of  accrued  interest  shall  become  due  together  with  the
         repayment of the Granted Loan. In the case of conversion interest shall
         accrue  until the Company has  provided  the Lender with all  documents
         required in connection with the issuance of new Preferred B pursuant to
         Subclause 3.6.

5.       TERMINATION FOR GOOD CAUSE

         The  Company  and the  Lender  shall  be  entitled  to  terminate  this
         Agreement  in writing  with  immediate  effect  for good cause  without
         notice. There shall be deemed good cause justifying termination by both
         parties  under the following  circumstances,  including but not limited
         to:

                                       2
<PAGE>

         (a)      the dissolution of the Company;

         (b)      the  opening of  insolvency  proceedings  with  respect to the
                  assets of the Company or the refusal to open such  proceedings
                  due to  insufficiency  of funds;  the filing of an application
                  with a court of competent  jurisdiction by the Company seeking
                  the  opening of  insolvency  proceedings  with  respect to the
                  assets of the Company;  the Company becoming unable or failing
                  generally to pay its debts as they become due;

         (c)      any  breach  by  the   Company  or  the  Lender  of   material
                  obligations under this Agreement, including but not limited to
                  the  repayment  of the Granted  Loan or the  accrued  interest
                  within the time limit;

         (d)      a change of control of the Company (save for the investment of
                  the Lender  itself);  and

         (e)      the exercise of the Conversion Right pursuant to Clause 3.

The Lender is  additionally  entitled to terminate this Agreement if the Company
rescinds the DNAPrint Investment  Agreement of September 2004. In this case, the
Lender may claim immediate  repayment of the Granted Loan and accrued but unpaid
interest or, at its sole  discretion,  exercise the Conversion Right pursuant to
Clause 3.

6.       NOTICES

6.1      All notices,  demands and other communications  between the Company and
         the Lender provided for or permitted hereunder shall be made in writing
         and shall be by  registered  or  certified  first  class  mail,  return
         receipt  requested,  facsimile,  courier  service,  overnight  mail  or
         personal delivery, if

         (a)      to the Company:   Biofrontera AG,  Hemmelrather Weg 201, 51377
                                    Leverkusen, Germany;

         (b)      to  DNAPrint:     DNAPrint  genomics,  Inc., 900 Cocoanut Ave.
                                    Sarasotar, FL 34236, USA,

         unless notified otherwise by the respective party.

7.       FINAL PROVISIONS

7.1      Each party to this  Agreement  shall bear its own costs in  relation to
         this  Agreement  and its  performance,  including  the  exercise of the
         Conversion Right.

7.2      No failure or delay on the part of any of the parties to this Agreement
         in the  exercise  or  implementation  of any  right,  power  or  remedy
         hereunder  shall operate as a waiver  thereof,  nor shall any single or
         partial exercise of any such right,  power or remedy preclude any other
         or further exercise  thereof or the exercise of any other right,  power
         or remedy.  The remedies provided for herein are cumulative and are not
         exclusive of any remedies that may be available.

7.3      Amendments  and  additions to this  Agreement and any waiver of and any
         consent to any departure from any provision of this Agreement  requires
         the consent of all parties and must be made in writing to be effective,
         to the extent that notarization is not required. This also applies to a
         waiver of the written form requirement.

                                       3
<PAGE>

7.4      This Agreement shall be governed exclusively by the laws of the Federal
         Republic of Germany.  The  application  of the provisions of the United
         Nations  Convention on the International Sale of Goods and German rules
         on Conflict of Laws is hereby explicitly  excluded.  To the extent that
         such an agreement is legally valid,  the courts of Frankfurt shall have
         exclusive jurisdiction over this Agreement.

7.5      Should  individual  terms of this  Agreement  be or become  invalid  or
         unenforceable or should this Agreement contain unintentional gaps, this
         shall not affect the validity of the remaining terms of this Agreement.
         In place of the invalid, unenforceable or missing term, such valid term
         which the parties would reasonably have agreed,  had they been aware at
         the  conclusion of this  Agreement  that the relevant term was invalid,
         unenforceable or missing, shall be deemed to have been agreed. Should a
         term of this  Agreement  be or become  invalid  because of the scope of
         performance for which it provides, then the agreed scope of performance
         shall be amended to correspond with the extent legally permitted.

7.6      The parties to this Agreement  shall execute such documents and perform
         such  further  acts  (including,  without  limitation,   obtaining  any
         consents,  exemptions,  authorizations  or other  actions by, or giving
         notices to, or making any filings with, any  governmental  authority or
         any other person) as may be  reasonably  required or desirable to carry
         out or to perform the provisions of this Agreement.

7.7      This  Agreement  is intended by the  parties as a final  expression  of
         their  agreement and intended to be a complete and exclusive  statement
         of the agreement and  understanding of the parties hereto in respect of
         the  subject-matter  hereof.  There  are  no  restrictions,   promises,
         warranties or  undertakings,  other than those set forth or referred to
         herein.   This   Agreement   supersedes   all  prior   agreements   and
         understandings between the parties with respect to such subject-matter.

Leverkusen, December 29, 2004           /s/
                                        ------------------------------------
                                        Biofrontera AG

Sarasota, December29, 2004              /s/
                                        ------------------------------------
                                        DNAPrint genomics Inc.

                                       4Exhibit 4.2

                                    AMENDMENT

         This Amendment to Funding Agreement is entered into as of the 30th day
of December, 2004, by and between Tony Frudakis ("Investor") and DNAPrint
genomics, Inc. (the "Company").

                              W I T N E S S E T H:

         WHEREAS, the parties hereto are parties to a Funding Agreement dated on
or about October 25, 2002, (the "Agreement"), pursuant to which the Investor has
advanced certain funds to the Company; and

         WHEREAS, the parties desire to memorialize the modifications in this
Amendment.

         NOW, THEREFORE, in consideration of the premises and the mutual
covenants contained herein, the parties agree as follows:

          1.   Capitalized terms used herein but not defined herein shall have
               the same meaning given to those in the Agreement.

          2.   The term of the Agreement and the Consideration associated
               therewith are hereby amended to extend such dates for repayment
               of any and all funds advanced pursuant to the Agreement, whether
               or not such advances are represented by independent promissory
               notes, until December 31, 2005, and the Investor shall take no
               action to collect any such funds unless and until such funds
               shall not have been repaid by December 31, 2005.

          3.   Except as explicitly modified herein, the Agreement shall remain
               in full force and effect.

         IN WITNESS WHEREOF, the parties have executed this Agreement as of the
date first above written.

                                                 DNAPrint genomics, Inc.

                                                 By: /s/ Richard Gabriel
                                                     --------------------------

                                                 /s/ Tony Frudakis
                                                 ------------------------------
                                                 Tony Frudakis

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00076-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00076-of-00352.parquet"}]]